Influence of Helicobacter pylori infection on PD‐1/PD‐L1 blockade therapy needs more attention
Influence of Helicobacter pylori infection on PD‐1/PD‐L1 blockade therapy needs more attention
复制标题
DOI：
10.1111/hel.12878
复制
发表时间：
--
期刊：
影响因子：
--
通讯作者：
Shigang Ding
中科院分区：
文献类型：
--
作者：
Yanyan Shi;Huiling Zheng;Mopei Wang;Shigang Ding
Background and objective: The tumor microenvironment and tumor immunity are crucially involved in tumor therapy. Immune checkpoint inhibitors targeting PD- 1/PD- L1 signal transduction have been widely used in tumor therapy and have shown ideal clinical efficacy. However, some kinds of cancers still do not respond to PD- 1/PD- L1 blockade therapy effectively, including gastric cancer. The related factors should be explored. Methods and results: This review summarizes the recent progression of understanding the influence of Helicobacter pylori infection on PD- 1/PD- L1 blockade therapy. Current pieces of evidence have indicated that H. pylori infection might affect the curative effect of tumor therapy associating with the induced immunomodulation. Conclusion: It is necessary to understand the overall integration of PD- 1/PD- L1 blockade therapy, the tumor microenvironment, and H. pylori infection. Much attention on the influence of H. pylori infection on the efficacy of tumor immunotherapy should be paid.
